Open-Label, Randomised Parallel-Group Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00728533
Recruitment Status : Withdrawn (Terminated due to awaiting data from Phase II study.)
First Posted : August 6, 2008
Last Update Posted : March 18, 2011
Information provided by:
Ferring Pharmaceuticals

January 18, 2008
August 6, 2008
March 18, 2011
Not Provided
Not Provided
To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (=0.5 ng/mL) during one year of treatment in prostate cancer patients. [ Time Frame: 3-month ]
Same as current
Complete list of historical versions of study NCT00728533 on Archive Site
  • To evaluate testosterone, PSA, LH, and FSH responses during one year of treatment. [ Time Frame: 3-month ]
  • To evaluate pharmacokinetic response. [ Time Frame: 3-month ]
  • To compare safety and tolerability profiles of different degarelix three-month dosing regimens. [ Time Frame: 3-month ]
Same as current
Not Provided
Not Provided
Open-Label, Randomised Parallel-Group Study
The Rationale of the Study is to Demonstrate That Degarelix Given at Three-month Dosing Intervals Will Produce and Maintain Androgen Deprivation in Prostate Cancer Patients Through Immediate and Prolonged Testosterone Suppression, and to Provide Confirmatory Evidence of the Safety of Degarelix.
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
Drug: Degarelix
Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
  • Experimental: 1
    • Starting dose of 240 mg (40 mg/mL) will be given on Day 0.
    • Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months
    Intervention: Drug: Degarelix
  • Experimental: 2
    • Starting dose of 240 mg (40 mg/mL) will be given on Day 0.
    • Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months.
    Intervention: Drug: Degarelix
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
Not Provided
Not Provided

Inclusion Criteria:

  • Patients, aged 18 years or older, with a histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
  • Screening testosterone level above the lower limit of normal range, globally defined as > 2.2 ng/mL.
  • Screening PSA level of =2 ng/mL. ECOG score of =2.
  • Life expectancy of at least one year.


Primary endpoint:

  • Probability of testosterone at castrate level (=0.5 ng/mL) from Day 28 through Day 364.

Secondary endpoints:

  • Probability of testosterone at castrate level (=0.5 ng/mL) from Day 56 through Day 364.
  • Serum levels of testosterone, LH, FSH, and PSA over time.
  • Time to PSA failure - defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir.
  • Plasma levels of degarelix over time.
  • Frequency and severity of adverse events.
  • Clinically significant changes in laboratory safety parameters.
  • Clinically significant changes in physical examinations, ECGs, vital signs, and body weight.
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
FE200486 CS26
Not Provided
Not Provided
Clinical Development Support, Ferring Pharmaceuticals
Ferring Pharmaceuticals
Not Provided
Study Director: Clinical Development Support Ferring Pharmaceuticals
Ferring Pharmaceuticals
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP